Holly Thacker, MD, is Director of the Center for Specialized Women’s Health at the Cleveland Clinic in Cleveland, Ohio, and Professor of Obstetrics and Gynecology and Women’s Health at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. She is the author of The Cleveland Clinic Guide to Menopause (2009) and Women’s Health: Your Body, Your Hormones, Your Choices (2007).
Dr. Thacker reports that she has served as a speaker for Amgen, Novartis, Novo Nordisk, and Shionogi; is a consultant for Myriad, Noven, and Pfizer; and is Executive Director of the National Speaking of Women’s Health Foundation.
THE BOTTOM LINE We need to look at the totality of the data on menopausal HT, evaluate our patients individually, treat those who are truly hormonally deficient and suffering, and counsel them that many of the harms linked to HT have been exaggerated.
The pendulum is finally swinging back toward a more balanced assessment of the benefits and risks of HT, indicating that it may be appropriate for primary prevention of cardiovascular disease, osteoporosis, and type 2 diabetes—and thus can potentially expand the lifespan. It’s up to us to communicate this fact to our patients.
TELL US WHAT YOU THINK! Share your thoughts on this article or on any topic relevant to ObGyns and women’s health practitioners. Tell us which topics you’d like to see covered in future issues, and what challenges you face in daily practice. We will consider publishing your letter and in a future issue. Send your letter to: firstname.lastname@example.org Please include the city and state in which you practice. Stay in touch! Your feedback is important to us!